Research & Development
Pharmacogenomic testing for better depression treatment
In the study, the patients being treated for major depressive disorder (MDD) who received pharmacogenomics testing also experienced better depression outcomes soon after they were tested.
July 13, 2022
Cerebrospinal fluid test helps pinpoint dementia disorders
The meta-analysis of studies involving about 10,000 people with neurological disorders showed that neurofilament light protein as measured with a commercially available immunoassay was elevated for people with neurological and psychiatric conditions. Results were broadly similar; however, frontotemporal dementia and HIV-related cognitive decline were differentiated from other dementias, and Parkinson's disease was differentiated from atypical parkinsonian conditions.
June 17, 2019
Page 1 of 1